These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31317658)

  • 21. Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants.
    Devreese KM
    Thromb Res; 2008; 123(2):404-11. PubMed ID: 18495217
    [No Abstract]   [Full Text] [Related]  

  • 22. Significantly Prolonged Prothrombin Time and Activated Partial Thromboplastin Time with no Bleeding Tendency: A Patient with Lupus Anticoagulant-Hypoprothrombinemia Syndrome Positive for Immunoglobulin M Anti-Phosphatidylserine/Prothrombin complex Antibodies.
    Fei Y; Tang N; Zhang H; Li G; Zhang H; Zhang C
    Semin Thromb Hemost; 2020 Jun; 46(4):507-511. PubMed ID: 31877567
    [No Abstract]   [Full Text] [Related]  

  • 23. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME; Cabiedes J; Reyes E; Cabral AR
    Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G; Valverde S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
    Kershaw G
    Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of dabigatran and rivarovaban on a prothrombinase-based assay for activated protein C resistance: a preliminary study in subjects heterozygous for factor V Leiden.
    Gessoni G; Valverde S; Gessoni F; Valle R
    Blood Transfus; 2015 Oct; 13(4):666-8. PubMed ID: 25761318
    [No Abstract]   [Full Text] [Related]  

  • 28. Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives.
    Chandler JB; Torres R; Rinder HM; Tormey CA
    Br J Haematol; 2014 Dec; 167(5):704-7. PubMed ID: 25041401
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
    Herskovits AZ; Lemire SJ; Longtine J; Dorfman DM
    Am J Clin Pathol; 2008 Nov; 130(5):796-804. PubMed ID: 18854273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis.
    Van Cott EM; Laposata M; Hartnett ME
    Blood Coagul Fibrinolysis; 2004 Jul; 15(5):393-7. PubMed ID: 15205587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
    Baig MA
    Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activated protein C resistance in normal and pre-eclamptic pregnancies.
    Paternoster DM; Stella A; Simioni P; Girolami A; Snijders D
    Gynecol Obstet Invest; 2002; 54(3):145-9. PubMed ID: 12571435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits.
    McGlasson DL; Fritsma GA
    Semin Thromb Hemost; 2013 Apr; 39(3):315-9. PubMed ID: 23468380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia.
    Houghton DE; Sud S; Moll S; Rollins-Raval MA
    Vasc Med; 2017 Dec; 22(6):527-528. PubMed ID: 28965480
    [No Abstract]   [Full Text] [Related]  

  • 35. A highly specific functional test for factor V leiden: A modified tissue factor assay for activated protein C resistance.
    Arkel YS; Ku D; Kamiyama M; Pajaro R; Alder H; Marchand A
    Haemostasis; 1997; 27(6):290-304. PubMed ID: 9731110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
    Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperprothrombinemia may result in scquired activated protein C reistance.
    Tripodi A; Chantarangkul V; Mannucci PM
    Blood; 2000 Nov; 96(9):3295-6. PubMed ID: 11203206
    [No Abstract]   [Full Text] [Related]  

  • 38. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study.
    Exner T; Ellwood L; Rubie J; Barancewicz A
    Thromb Haemost; 2013 Apr; 109(4):762-5. PubMed ID: 23364321
    [No Abstract]   [Full Text] [Related]  

  • 39. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
    Chaireti R; Jennersjö C; Lindahl TL
    Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect?
    Shen YM; Cimo ML; Bai Y; Frenkel E; Sarode R
    Clin Appl Thromb Hemost; 2011; 17(6):E190-5. PubMed ID: 21406411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.